scholarly journals Mechanism of Human Hematopoietic Stem Cell Loss during Ex Vivo Manipulation and Gene Transfer

2018 ◽  
Vol 64 ◽  
pp. S103
Author(s):  
Archana Shrestha ◽  
Tomoyasu Higashimoto ◽  
Sydney Felker ◽  
Anastacia Loberg ◽  
Rajeswari Jayavaradhan ◽  
...  
Keyword(s):  
Stem Cell ◽  
Gene Transfer ◽  
Hematopoietic Stem Cell ◽  
Ex Vivo ◽  
Cell Loss ◽  
Hematopoietic Stem

Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up

Blood ◽  
2010 ◽  
Vol 116 (26) ◽  
pp. 6123-6132 ◽  
Author(s):  
Richard K. Burt ◽  
Robert M. Craig ◽  
Francesca Milanetti ◽  
Kathleen Quigley ◽  
Paula Gozdziak ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Crohn Disease ◽  
Ex Vivo ◽  
Activity Index ◽  
Clinical Relapse ◽  
Hematopoietic Stem

Abstract We evaluated the safety and clinical outcome of autologous nonmyeloablative hematopoietic stem cell transplantation (HSCT) in patients with severe Crohn disease (CD) defined as a Crohn Disease Activity Index (CDAI) greater than 250, and/or Crohn Severity Index greater than 16 despite anti–tumor necrosis factor therapy. Stem cells were mobilized from the peripheral blood using cyclophosphamide (2.0 g/m2) and G-CSF (10 μg/kg/day), enriched ex vivo by CD34+ selection, and reinfused after immune suppressive conditioning with cyclophosphamide (200 mg/kg) and either equine antithymocyte globulin (ATG, 90 mg/kg) or rabbit ATG (6 mg/kg). Eighteen of 24 patients are 5 or more years after transplantation. All patients went into remission with a CDAI less than 150. The percentage of clinical relapse-free survival defined as the percent free of restarting CD medical therapy after transplantation is 91% at 1 year, 63% at 2 years, 57% at 3 years, 39% at 4 years, and 19% at 5 years. The percentage of patients in remission (CDAI < 150), steroid-free, or medication-free at any posttransplantation evaluation interval more than 5 years after transplantation has remained at or greater than 70%, 80%, and 60%, respectively. This trial was registered at www.clinicaltrials.gov as NCT0027853.

scholarly journals Efficient gene transfer into hematopoietic stem cell, mesenchymal stem cell, and ES cell by modified adenovirus vectors

Ensho Saisei ◽  
2005 ◽  
Vol 25 (5) ◽  
pp. 447-451
Author(s):  
Hiroyuki Mizuguchi ◽  
Kenji Kawabata ◽  
Fuminori Sakurai ◽  
Takao Hayakawa
Keyword(s):  
Stem Cell ◽  
Gene Transfer ◽  
Mesenchymal Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Es Cell ◽  
Hematopoietic Stem ◽  
Efficient Gene ◽  
Adenovirus Vectors

scholarly journals Terminal Differentiation Is the Major Route of Hematopoietic Stem Cell Loss During Chronic Infection

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Katherine King ◽  
Katie Matatall ◽  
Siyi Chen ◽  
Mira Jeong ◽  
Deqiang Sun ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Chronic Infection ◽  
Terminal Differentiation ◽  
Cell Loss ◽  
Hematopoietic Stem ◽  
Major Route
Sign in / Sign up

Export Citation Format

Share Document